The EU Commission fines a pharmaceutical company €7.5M for providing inaccurate information during review of an acquisition application (Merck / Sigma-Aldrich)

On 3 May 2021, the EC fined Sigma-Aldrich EUR 7.5 million for providing incorrect or misleading information during the EC’s review of Merck’s planned acquisition of the company. Background On 21 April 2015, Merck notified the EC of its plan to acquire Sigma-Aldrich. On 15 June 2015, the EC approved the proposed acquisition subject to the divestiture of certain Sigma-Aldrich assets, which would address the competition concerns identified in markets for specific laboratory chemicals (Decision C (2015) 4188 final of 15 June 2015 in Case M.7435, Merck/Sigma-Aldrich). During the course of the divestment process, the EC became aware of a Sigma-Aldrich innovation

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • McDermott Will & Emery (Paris)
  • McDermott Will & Emery (Washington)

Quotation

Frédéric Pradelles, Mary Hecht, The EU Commission fines a pharmaceutical company €7.5M for providing inaccurate information during review of an acquisition application (Merck / Sigma-Aldrich), 3 May 2021, e-Competitions May 2021, Art. N° 106714

Visites 80

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues